New Insight Into Hyperglycemia Risk With PI3K Inhibitor for Breast Cancer
Severe hyperglycemia has emerged as a common side effect among patients with PIK3CA-mutated breast cancer treated with the PI3K inhibitor alpelisib (Piqray), especially patients treated outside a clinical trial, a retrospective study showed. Overall, 61.5% of 247 patients developed any degree of hyperglycemia, which reached grade 3/4 severity in 29%. Any grade of hyperglycemia occurred […]